Skip to main content
. 2021 Oct;12(5):2423–2437. doi: 10.21037/jgo-20-610

Table 2. Mutation and biomarker incidence.

Name Incidence (%) Incidence ratio Technique
MSH2 100 92/92 IHC
MSH6 100 90/90 IHC
MLH1 98.9 91/92 IHC
PMS2 98.9 87/88 IHC
EGFR 97.7 43/44 IHC
PD-1 68.8 44/64 IHC
PTEN 68.1 64/94 IHC
PD-L1 40.5 119/294 IHC
PIK3CA 28.1 62/221 NGS
PIK3CA 24.2 15/62 NGS hot spot
KMT2D 19.5 36/185 NGS
KMT2C 16.2 19/177 NGS
FBXW7 12.9 8/62 NGS hot spot
TP53 12. 25/208 NGS
PTEN 10.8 22/204 NGS
FBXW7 10.3 20/195 NGS
TMB 6.7 14/209 NGS
PIK3CA 5.4 11/205 CNA
TP53 5 3/60 NGS hot spot
ARID1A 4.8 4/84 NGS
ATRX 4.1 3/73 NGS
APC 3.8 8/212 NGS
NOTCH1 3.4 7/204 NGS
RB1 3.3 2/61 NGS hot spot
AKT1 3.2 2/62 NGS hot spot
KRAS 3.2 2/62 NGS hot spot
TRK A/B/C 3.1 2/64 IHC
BCL6 2.9 6/205 CNA
NFIB 2.9 6/205 CNA
PBRM1 2.9 6/206 NGS
EP300 2.9 5/174 NGS
CDKN2A 2.8 6/216 NGS
KRAS 2.7 6/221 NGS
FGF19 2.5 5/204 CNA
TFRC 2.4 5/205 CNA
FGF4 2.4 5/208 CNA
FGF3 2.4 5/209 CNA
KDM5C 2.4 3/126 NGS
FGFR3 2.3 5/214 NGS
AKT1 2.3 5/218 NGS
BAP1 2.3 5/219 NGS
CYLD 2.1 4/191 NGS
RB1 2 4/197 NGS
PIK3R1 2 4/204 NGS
KLHL6 2 4/205 CNA
CCND1 1.9 4/210 CNA
BRCA2 1.9 4/215 NGS
MUTYH 1.8 4/217 NGS
ERBB2 1.8 4/219 NGS
ZNF703 1.5 3/203 CNA
CALR 1.5 3/205 CNA
ETV5 1.5 3/205 CNA
LPP 1.5 3/205 CNA
LYL1 1.5 3/205 CNA
PSIP1 1.5 3/205 CNA
SMAD2 1.5 3/205 CNA
EGFR 1.4 3/208 CNA
FH 1.4 3/215 NGS
CTNNB1 1.4 3/216 NGS
HRAS 1.4 3/221 NGS
MSI 1.3 2/156 NGS
CREBBP 1.1 2/188 NGS
NSD1 1 2/198 NGS
ARID2 1 2/200 NGS
MYB 1 2/202 CNA
ADGRA2 1 2/203 CNA
FANCG 1 2/204 CNA
PRRX1 1 2/204 CNA
KEAP1 1 2/205 CNA
KRAS 1 2/205 CNA
MALT1 1 2/205 CNA
NSD3 1 2/205 CNA
SMAD4 1 2/205 CNA
SS18 1 2/205 CNA
FGFR1 1 2/209 CNA
MSH6 1 2/210 NGS
ERCC2 0.9 2/213 NGS
ATM 0.9 2/214 NGS
STK11 0.9 2/216 NGS
BRAF 0.9 2/217 NGS
ERBB3 0.9 2/218 NGS
BRCA1 0.9 2/219 NGS

IHC, immunohistochemistry; NGS, next-generation sequencing; CNA, copy number alteration.